Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Exclusion Criteria

• •Hospitalized at the time of study entry (unless discharge is expected within 10 days after entry into the study)
• •Receiving chronic oxygen therapy or mechanical ventilation at the time of study entry (including continuous positive airway pressure \[CPAP\])
• •Congenital heart disease (CHD) (children with medically or surgically corrected \[closed\] patent ductus arteriosus and no other CHD may be enrolled)
• •Evidence of infection with hepatitis A, B, or C virus
• •Known renal impairment, hepatic dysfunction, chronic seizure disorder, or immunodeficiency or HIV infection (a child of a mother with known HIV infection must be proven to be uninfected at the time of enrollment)
• •Suspected serious allergic or immune-mediated events with prior receipt of palivizumab
• •Acute illness or progressive clinical disorder
• •Active infection, including acute RSV infection, at the time of enrollment
• •Previous reaction to intravenous immunoglobulin (IGIV), blood products, or other foreign proteins
• •Received within the past 120 days or currently receiving immunoglobulin products (such as RSV-IGIV \[RespiGam\], IVIG, or palivizumab) or any investigational agents
• •Previous participation in a clinical trial of motavizumab
• •Currently participating in any investigational study